Paniltri (Hydrochlorothiazide, Ramipril, Amlodipine Besilate)

Paniltri, a fixed‑dose combination antihypertensive, is indicated for the management of elevated blood pressure.

• Hypertension: provides effective blood pressure reduction in adults with primary hypertension.
• Resistant hypertension: offers an additional therapeutic option when blood pressure remains uncontrolled on two agents.
• Hypertension with fluid retention: helps control blood pressure and reduces peripheral edema by combining a diuretic with vasodilators.
• Hypertension in chronic kidney disease: slows renal function decline by inhibiting the renin‑angiotensin system.

• Hydrochlorothiazide acts on the distal convoluted tubule to inhibit NaCl reabsorption, promoting diuresis. Ramipril blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Amlodipine Besilate selectively inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation. Together these actions decrease plasma volume, systemic vascular resistance and cardiac afterload, resulting in lowered arterial pressure.

Paniltri may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Peripheral edema: swelling of ankles or feet.
• Cough: dry, persistent throat irritation.
• Fatigue: feeling unusually tired or weak.
• Increased urination: more frequent need to void.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips or throat requiring emergency care.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Electrolyte imbalance: especially hyperkalemia or hyponatremia.
• Acute renal impairment: sudden decline in kidney function.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Renal function assessment: evaluate serum creatinine and eGFR periodically.
• Electrolyte surveillance: check potassium and sodium levels, especially with diuretic use.
• Pregnancy and lactation: avoid use unless clearly indicated, as risks may outweigh benefits.
• Elderly patients: start at lower doses and monitor for orthostatic symptoms.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Paniltri can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Aliskiren: combined renin inhibition may cause renal dysfunction.
• NSAIDs: can blunt antihypertensive effect and increase renal risk.
• Potassium‑sparing agents or supplements: heightened risk of hyperkalemia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., clarithromycin): may increase amlodipine concentrations.
• Other antihypertensives (e.g., beta‑blockers): additive hypotensive effect.
• Non‑potassium‑sparing diuretics: may exacerbate electrolyte disturbances.